These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 30347827

  • 1. Oncotoxic Properties of Serotonin Transporter Inhibitors and 5-HT1A Receptor Ligands.
    Walory J, Mielczarek L, Jarończyk M, Koronkiewicz M, Kossakowski J, Bugno R, Bojarski AJ, Chilmonczyk Z.
    Int J Mol Sci; 2018 Oct 20; 19(10):. PubMed ID: 30347827
    [Abstract] [Full Text] [Related]

  • 2. Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT1A receptor in the mouse striatum and prefrontal cortex.
    Hagino Y, Hall FS, Uhl GR, Sora I, Ikeda K.
    Neuropsychopharmacol Rep; 2021 Mar 20; 41(1):91-101. PubMed ID: 33547882
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
    van Amsterdam C, Seyfried CA.
    Psychopharmacology (Berl); 2014 Jun 20; 231(12):2547-58. PubMed ID: 24419272
    [Abstract] [Full Text] [Related]

  • 4. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
    Herold F, Chodkowski A, Izbicki Ł, Turło J, Dawidowski M, Kleps J, Nowak G, Stachowicz K, Dybała M, Siwek A, Mazurek AP, Mazurek A, Pluciński F.
    Eur J Med Chem; 2011 Jan 20; 46(1):142-9. PubMed ID: 21093118
    [Abstract] [Full Text] [Related]

  • 5. Effects of the potential antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate] a combined sigma and 5-HT1A ligand: modulation of neuronal activity in the dorsal raphe nucleus.
    Bermack JE, Haddjeri N, Debonnel G.
    J Pharmacol Exp Ther; 2004 Aug 20; 310(2):578-83. PubMed ID: 15044555
    [Abstract] [Full Text] [Related]

  • 6. 5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms.
    Shimizu S, Mizuguchi Y, Tatara A, Kizu T, Andatsu S, Sobue A, Fujiwara M, Morimoto T, Ohno Y.
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct 01; 46():86-91. PubMed ID: 23838274
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Discovery of DSP-1053, a novel benzylpiperidine derivative with potent serotonin transporter inhibitory activity and partial 5-HT1A receptor agonistic activity.
    Yoshinaga H, Nishida T, Sasaki I, Kato T, Oki H, Yabuuchi K, Toyoda T.
    Bioorg Med Chem; 2018 May 01; 26(8):1614-1627. PubMed ID: 29456112
    [Abstract] [Full Text] [Related]

  • 12. Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.
    Cussac D, Palmier C, Finana F, De Vries L, Tardif S, Léger C, Bernois S, Heusler P.
    J Pharmacol Exp Ther; 2009 Oct 01; 331(1):222-33. PubMed ID: 19605522
    [Abstract] [Full Text] [Related]

  • 13. Bell-shaped agonist activation of 5-HT1A receptor-coupled Gαi3 G-proteins: Receptor density-dependent switch in receptor signaling.
    Newman-Tancredi A, Cussac D, Ormière AM, Lestienne F, Varney MA, Martel JC.
    Cell Signal; 2019 Nov 01; 63():109383. PubMed ID: 31376526
    [Abstract] [Full Text] [Related]

  • 14. Differential involvement of 5-HT(1A) and 5-HT(1B/1D) receptors in human interferon-alpha-induced immobility in the mouse forced swimming test.
    Zhang H, Wang W, Jiang Z, Shang J, Zhang L.
    Arzneimittelforschung; 2010 Nov 01; 60(3):109-15. PubMed ID: 20422941
    [Abstract] [Full Text] [Related]

  • 15. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
    Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB.
    J Med Chem; 2011 May 12; 54(9):3206-21. PubMed ID: 21486038
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of 5-HT1A, 5-HT2A and 5-HT2C receptor agonists and antagonists on responding for a conditioned reinforcer and its enhancement by methylphenidate.
    Fletcher PJ, Zeeb FD, Browne CJ, Higgins GA, Soko AD.
    Psychopharmacology (Berl); 2017 Mar 12; 234(5):889-902. PubMed ID: 28097374
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Analysis of mechanisms for memory enhancement using novel and potent 5-HT1A receptor ligands.
    Pittalà V, Siracusa MA, Salerno L, Romeo G, Modica MN, Madjid N, Ogren SO.
    Eur Neuropsychopharmacol; 2015 Aug 12; 25(8):1314-23. PubMed ID: 25963581
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.